By Dr. Azad Moopen, Founder and Chairman, Aster DM Healthcare
The year 2025 marked a defining inflection point for Indian healthcare, shaped by decisive government reforms and policy interventions that expanded inclusion, improved affordability, and reinforced long-term confidence in the sector.
The rationalisation of GST on critical cancer and life-saving drugs will play a vital role in lowering treatment costs reinforcing the government’s commitment to making essential therapies more accessible. The continued expansion of Ayushman Bharat has further strengthened financial protection and brought quality healthcare within reach of millions, particularly across underserved communities. The year also saw sustained private equity interest in India’s healthcare sector, reflecting investor conviction in its scale, structural growth, and long-term value creation potential and a strong wave of healthcare and MedTech startups focused on diagnostics, digital health and specialised care delivery, reflecting long-term confidence in the sector’s fundamentals.
At Aster, we mirrored this momentum with accelerated investments by expanding bed capacity, strengthening precision oncology and digital platforms. We also completed regulatory measures towards our merger process, positioning Aster as one of India’s leading integrated healthcare networks.
As we look to 2026, the opportunity lies in translating scale and capital into outcomes. This will require faster regulatory clearances, sharper focus on tier-2 and tier-3 infrastructure, sustained workforce skilling, and stronger public–private collaboration. Addressing talent shortages while enabling innovation will be critical for ensuring that quality healthcare remains accessible, affordable and sustainable for every Indian family. For us at Aster, we are looking ahead to the completion of the merger with Quality Care India by Q1 FY27, and the combined entity is expected to become one of India’s top three hospital operators.
